90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma entity whose prognosis for high-risk patients is poor. Aggressive salvage treatments to improve patient outcome have been unsatisfactory. Therefore, we evaluated the efficacy of yttrium-90-ibritumomab tiuxetan (Zevalin®; (90)Y-IT) consolidation after early salvage chemotherapy with autologous stem cell transplantation. Thirty-seven patients with intermediate-high risk DLBCL not in complete remission (CR) after three cycles of rituximab, cyclophosphomide, doxorubicin, vincristine and prednisone (R-CHOP) were assessed retrospectively. After early salvage treatment, 70% achieved CR and 30% partial remission. Twenty patients underwent additional consolidation with (90)Y-IT. During the 3-year follow-up, 50% in the (90)Y-IT-treated group experienced relapse compared to 82.3% in the other cohort (p=0.002). Progression- and disease-free survival were significantly longer in the (90)Y-IT group. However, probably due to the relatively short follow-up period, no difference in overall survival was observed. (90)Y-IT consolidation after early salvage chemotherapy improves treatment responses and reduces the percentage of relapses without significant additional toxicities.

• Authors: Patrizia Mondello, Vincenzo Pitini, Carmela Arrigo, Enrico Derenzini, Michael Mian
• Journal: Anticancer research (Anticancer Res) Vol. 34 Issue 9 Pg. 5121-5 (Sep 2014) ISSN: 1791-7530 [Electronic] Greece
• PMID: 25202102 (Publication Type: Journal Article)
• Copyright: Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• R-CHOP protocol
• Rituximab
• ibritumomab tiuxetan
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Adult
• Antibodies, Monoclonal (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Murine-Derived (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Consolidation Chemotherapy
• Cyclophosphamide (therapeutic use)
• Doxorubicin (therapeutic use)
• Female
• Follow-Up Studies
• Hematopoietic Stem Cell Transplantation
• Humans
• Lymphoma, Large B-Cell, Diffuse (drug therapy, mortality, pathology, therapy)
• Male
• Middle Aged
• Neoplasm Staging
• Prednisone (therapeutic use)
• Retrospective Studies
• Rituximab
• Salvage Therapy
• Transplantation, Autologous
• Treatment Outcome
• Vincristine (therapeutic use)